-+ 0.00%
-+ 0.00%
-+ 0.00%

BioCardia says FDA confirms CardiAMP HF II trial may support PMA for CardiAMP cell therapy in ischemic HFrEF

PUBT·06/05/2026 12:02:09
Listen to the news
BioCardia says FDA confirms CardiAMP HF II trial may support PMA for CardiAMP cell therapy in ischemic HFrEF
  • BioCardia received FDA meeting minutes indicating its ongoing CardiAMP Heart Failure II trial may support a PMA filing for CardiAMP in ischemic HFrEF.
  • FDA feedback points to completed CardiAMP HF clinical data as supportive evidence, with additional trial evidence still needed to underpin a marketing application.
  • No new trial results were presented in the announcement; the key update was a regulatory pathway signal that could accelerate commercialization planning.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606050800PRIMZONEFULLFEED9732327) on June 05, 2026, and is solely responsible for the information contained therein.